Capital Advisors Inc. OK cut its stake in Abbott Laboratories (NYSE:ABT) by 2.0% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,406 shares of the healthcare product maker’s stock after selling 624 shares during the period. Capital Advisors Inc. OK’s holdings in Abbott Laboratories were worth $1,478,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Sanders Morris Harris LLC grew its holdings in Abbott Laboratories by 0.3% during the 2nd quarter. Sanders Morris Harris LLC now owns 4,986 shares of the healthcare product maker’s stock worth $242,000 after acquiring an additional 16 shares in the last quarter. St. Louis Trust Co grew its holdings in Abbott Laboratories by 0.4% during the 2nd quarter. St. Louis Trust Co now owns 4,904 shares of the healthcare product maker’s stock worth $238,000 after acquiring an additional 20 shares in the last quarter. Alpha Windward LLC grew its holdings in Abbott Laboratories by 0.6% during the 2nd quarter. Alpha Windward LLC now owns 5,434 shares of the healthcare product maker’s stock worth $264,000 after acquiring an additional 30 shares in the last quarter. Lakeview Capital Partners LLC grew its holdings in Abbott Laboratories by 0.6% during the 2nd quarter. Lakeview Capital Partners LLC now owns 5,691 shares of the healthcare product maker’s stock worth $277,000 after acquiring an additional 33 shares in the last quarter. Finally, Johanson Financial Advisors Inc. grew its holdings in Abbott Laboratories by 0.5% during the 2nd quarter. Johanson Financial Advisors Inc. now owns 7,017 shares of the healthcare product maker’s stock worth $343,000 after acquiring an additional 37 shares in the last quarter. Hedge funds and other institutional investors own 69.99% of the company’s stock.

Several research analysts have issued reports on ABT shares. Zacks Investment Research upgraded shares of Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a report on Tuesday, October 31st. Royal Bank Of Canada reiterated a “buy” rating and set a $55.00 target price on shares of Abbott Laboratories in a report on Tuesday, October 3rd. Bank of America Corporation reiterated a “buy” rating and set a $60.00 target price (up from $56.00) on shares of Abbott Laboratories in a report on Wednesday, October 4th. Jefferies Group LLC reiterated a “buy” rating and set a $65.00 target price on shares of Abbott Laboratories in a report on Thursday, October 19th. Finally, Citigroup Inc. reiterated a “neutral” rating on shares of Abbott Laboratories in a report on Thursday, October 19th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $56.81.

In other Abbott Laboratories news, insider Jaime Contreras sold 52,700 shares of the firm’s stock in a transaction that occurred on Friday, September 22nd. The shares were sold at an average price of $51.97, for a total transaction of $2,738,819.00. Following the completion of the transaction, the insider now directly owns 58,739 shares of the company’s stock, valued at approximately $3,052,665.83. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $56.21, for a total transaction of $5,430,054.63. Following the transaction, the executive vice president now directly owns 142,082 shares of the company’s stock, valued at $7,986,429.22. The disclosure for this sale can be found here. Insiders sold a total of 308,939 shares of company stock valued at $16,835,789 over the last ninety days. 0.76% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “Abbott Laboratories (ABT) Shares Sold by Capital Advisors Inc. OK” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/abbott-laboratories-abt-shares-sold-by-capital-advisors-inc-ok/1720912.html.

Abbott Laboratories (NYSE:ABT) opened at $55.80 on Thursday. The company has a market cap of $97,682.52, a P/E ratio of 23.29, a P/E/G ratio of 2.10 and a beta of 1.06. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.69 and a quick ratio of 2.26. Abbott Laboratories has a 1 year low of $37.38 and a 1 year high of $56.69.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.01. The firm had revenue of $6.83 billion during the quarter, compared to analyst estimates of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. Abbott Laboratories’s revenue was up 28.8% on a year-over-year basis. During the same period last year, the firm posted $0.59 EPS. research analysts anticipate that Abbott Laboratories will post 2.49 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Investors of record on Friday, October 13th were given a $0.265 dividend. This represents a $1.06 annualized dividend and a dividend yield of 1.90%. The ex-dividend date of this dividend was Thursday, October 12th. Abbott Laboratories’s payout ratio is currently 83.47%.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with Analyst Ratings Network's FREE daily email newsletter.